UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants. The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Radiation oncologists urge lawmakers to act as Medicare cuts and private payer tactics push cancer clinics toward closing

Radiation oncologists are warning lawmakers that recent Medicare policy changes threaten the viability of community cancer clinics.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Clinical Trials & Tribulations

Protecting the cure: Why the future of radiation oncology must be precision-guided

Radiation therapy has been a cornerstone of cancer care since 1896. For more than a century, the central challenge has remained unchanged: How to eradicate tumors while preserving the normal tissues that allow patients not only to survive, but to thrive after treatment.

Radiation oncologists hit hard after Medicare cuts, ASTRO survey finds

Two-thirds of radiation oncologists surveyed by the American Society for Radiation Oncology in March are seeing Medicare reimbursements decline by 10% or more, according to a report published on April 1.

Small molecule inhibitor blocks prostate cancer bone metastasis

Findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine, published in Pharmacological Research, show that a targeted small molecule inhibitor, IVMT-Rx-4, may prevent prostate tumors from spreading to an advanced and incurable stage in the bones.

April 03, 2026

Vol.52 No.13

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

YOU MAY BE INTERESTED IN

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

Radiation oncologists urge lawmakers to act as Medicare cuts and private payer tactics push cancer clinics toward closing

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Protecting the cure: Why the future of radiation oncology must be precision-guided

Radiation oncologists hit hard after Medicare cuts, ASTRO survey finds

Small molecule inhibitor blocks prostate cancer bone metastasis

Renew today!

Subscriber content

Never miss an issue!

Login